Ulf Blom - Enzymatica AB Insider

Enzymatica AB -- Sweden Stock  

SEK 3.61  0.19  5.00%

Executive VP of Marketing and Operations

Mr. Ulf Blom has served as Executive Vice President Marketing and Operations at Enzymatica AB since 2011. He was Member of the Company Board of Directors from 2007 until May 6, 2013. He is CoFounder of the Company. He holds a MS degree in Economics and Business Administration and has over 15 years of experience in various positions within marketing and sales in the pharmaceutical industry, both nationally and internationally, including such companies as Novo Nordisk, Astra Zeneca and ALK. He also has experience in all strategic phases of drug commercialization on a global scale. He is Board Member and CEO of Medzyme Invest Oresund AB and Board Member of Enzymatica Care AB and Idogen AB.
Age: 51  EVP Since 2013      
46 4 62 86 31 00  http://www.enzymatica.se

Management Efficiency

The company has return on total asset (ROA) of (12.74) % which means that it has lost $12.74 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (24.88) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 8.02 M in total debt with debt to equity ratio (D/E) of 7.2 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Enzymatica AB has Current Ratio of 1.81 which is within standard range for the sector.

Entity Summary

Enzymatica AB , a life science company, develops and sells medical device products against infectious-related diseases. The company was founded in 2007 and is headquartered in Lund, Sweden. Enzymatica AB operates under Pharmaceuticals And Biosciences classification in Sweden and traded on Stockholm Stock Exchange exchange. It employs 21 people.Enzymatica AB (ENZY) is traded on Stockholm Stock Exchange in Sweden. It is located in Ideon Science Park and employs 21 people.

Did you try this?

Run Price Exposure Probability Now

Price Exposure Probability

Analyze equity upside and downside potential for a given time horizon across multiple markets
Hide  View All  NextLaunch Price Exposure Probability

Fix Portfolio

Optimize Your Risk-Return Tradeoff
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Enzymatica AB to your portfolio

Top Management

Enzymatica AB Leadership Team
Jonas Forsberg, Director, MBA
Bengt Baron, Chairman, MBA
Mats Clarsund, President, Ph.D
Anders Jungbeck, Director
Nils Siegbahn, Director, Ph.D
Bengt Jondell, CFO
Claus Egstrand, Executive
Sigurgeir Gudlaugsson, Director
Ulf Blom, EVP
Gun Rydhog, Director
Louise Nicolin, Director, MBA
Anna Isaksson, President
Therese Filmersson, CFO
Monica Wallter, Director
Marianne Alexandersson, Director
Hans Pihl, Director
Gudmundur Palmason, Director, MBA
Jorgen Rexo, President
Mats Andersson, Director
Fredrik Lindberg, Director, Ph.D
Lennart Nilsson, Chairman
Johan Lindvall, President
Johan Wennerholm, CFO

Stock Performance

Enzymatica AB Performance Indicators